Auscann Group Holdings Ltd
ASX:AC8

Watchlist Manager
Auscann Group Holdings Ltd Logo
Auscann Group Holdings Ltd
ASX:AC8
Watchlist
Price: 0.04 AUD -4.76% Market Closed
Market Cap: 17.6m AUD

Operating Margin

-460.7%
Current
Improving
by 277.3%
vs 3-y average of -738.1%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-460.7%
=
Operating Income
AU$-9.4m
/
Revenue
AU$2m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-460.7%
=
Operating Income
AU$-9.4m
/
Revenue
AU$2m

Peer Comparison

Country Company Market Cap Operating
Margin
AU
Auscann Group Holdings Ltd
ASX:AC8
17.6m AUD
Loading...
US
Eli Lilly and Co
NYSE:LLY
982.2B USD
Loading...
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
Loading...
US
Johnson & Johnson
NYSE:JNJ
526.1B USD
Loading...
CH
Roche Holding AG
SIX:ROG
277.8B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
217.9B GBP
Loading...
CH
Novartis AG
SIX:NOVN
221.8B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
270.7B USD
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK
Loading...
IE
Endo International PLC
LSE:0Y5F
213.9B USD
Loading...
US
Pfizer Inc
NYSE:PFE
145.8B USD
Loading...
No Stocks Found

Market Distribution

Lower than 85% of companies in Australia
Percentile
15th
Based on 276 companies
15th percentile
-460.7%
Low
-1 321 700% — -7.9%
Typical Range
-7.9% — 20%
High
20% — 928.8%
Distribution Statistics
Australia
Min -1 321 700%
30th Percentile -7.9%
Median 10%
70th Percentile 20%
Max 928.8%

Auscann Group Holdings Ltd
Glance View

Market Cap
17.6m AUD
Industry
Pharmaceuticals

AusCann Group Holdings Ltd. engages in development, production, and distribution of cannabinoid-based medicines within Australia and internationally. The company is headquartered in Perth, Western Australia. The firm focuses on providing healthcare professionals and veterinarians with pharmaceutical and nutraceutical products to support the treatment of their patients. Its controlled-dose technology platform, Neuvis, is for delivering cannabinoids to human patients through CannPal Animal Therapeutics Pty Ltd. DermaCann is its lead cannabidiol (CBD) derived nutraceutical in development for healthy skin and immune function in dogs with dermatological conditions. CPAT-01 is a liquid, oral veterinary medicine containing tetrahydrocannabinol (THC) and CBD whole plant extracts in a combined ratio to cure pain and inflammation in dogs. CPAT-01 is in Phase II clinical trials. AusCann Operations Pty Ltd and CannPal Animal Therapeutics Limited are its subsidiaries.

AC8 Intrinsic Value
Not Available
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-460.7%
=
Operating Income
AU$-9.4m
/
Revenue
AU$2m
What is Auscann Group Holdings Ltd's current Operating Margin?

The current Operating Margin for Auscann Group Holdings Ltd is -460.7%, which is above its 3-year median of -738.1%.

How has Operating Margin changed over time?

Over the last 3 years, Auscann Group Holdings Ltd’s Operating Margin has increased from -3 214% to -460.7%. During this period, it reached a low of -3 214% on Dec 1, 2020 and a high of -277.1% on Jun 30, 2022.

Back to Top